viropharma incorporated pharmaceutical company developed sold drugs addressed serious diseases treated physician specialists hospital settings company focused product development activities viruses human disease including caused cytomegalovirus cmv hepatitis c virus hcv infections purchased shire shire paying around billion company deal finalized january viropharma member nasdaq biotechnology index sp
company strategic relationships glaxosmithkline scheringplough sanofiaventis viropharma acquired lev pharmaceuticals merger
history
viropharma incorporated founded claude h nash chief executive officer mark mckinlay vice president research development marc collett vice president discovery research johanna griffin vice president business development guy d diana vice president chemistry research none founders still company
november shire plc acquired viropharma billion
board directors
michel de rosen chairman since september president chief executive officer since august director since may
vincent j milano president chief executive officer since march director since march
paul brooke director since february
william d claypool director since december
michael r dougherty director since january
robert j glaser director since august
john r leone director since january
howard h pien director since
management team
vincent j milano president chief executive officer
daniel b soland vice president chief operating officer
thomas f doyle vice president strategic initiatives
colin broom vice president chief scientific officer
robert g pietrusko vice president global regulatory affairs quality
j peter wolf vice president general counsel
products
marketed products
vancocin pulvules hcl licensed eli lilly oral vancocin antibiotic treatment staphylococcal enterocolitis antibiotic associated pseudomembranous colitis caused clostridium difficile
pipeline
maribavir oral antiviral drug candidate licensed glaxosmithkline prevention treatment human cytomegalovirus disease hematopoietic stem cellbone marrow transplant patients february viropharma announced united states food drug administration fda granted company fast track status maribavir
march company announced phase ii study maribavir demonstrated prophylaxis maribavir displays strong antiviral activity measured statistically significant reduction rate reactivation cmv recipients hematopoietic stem cellbone marrow transplants intenttotreat analysis first days transplant number subjects required preemptive anticmv therapy statistically significantly reduced pvalue maribavir groups compared placebo group placebo vs maribavir mg twice daily mg daily mg twice daily respectively
viropharma conducted phase iii clinical study evaluate prophylactic use prevention cytomegalovirus disease recipients allogeneic stem cell transplant patients february viropharma announced phase iii study failed achieve goal showing significant difference maribavir placebo reducing rate cmv disease
failed products
oral pleconaril viropharmas first compound licensed sanofi pleconaril active viruses picornavirus family viropharmas first indication enteroviral meningitis indication abandoned clinical trials demonstrate efficacy
viropharma submitted new drug application pleconaril fda common cold fda antiviral advisory committee recommended company failed show adequate safety fda subsequently issued notapprovable letter
november viropharma licensed pleconaril scheringplough developing intranasal formulation common cold asthma exacerbations scheringplough development pipeline august scheringplough started phase ii clinical trial
references
references
long road ahead viropharma motley fool september
mcdonald lc killgore ge thompson et al emergence epidemic toxin gene variant strain clostridium difficile responsible outbreaks united states n engl j med
us centers disease control prevention report severe clostridium difficileassociated disease populations previously low risk four states
lu h thomas maribavir viropharma curr opin investig drugs
fleischer r laessig k safety efficacy evaluation pleconaril treatment common cold clin infect dis doi pmid
hayden fg herrington dt coats tl kim k cooper ec villano sa liu hudson pevear dc collett m mckinlay m efficacy safety oral pleconaril treatment colds due picornaviruses adults results doubleblind randomized placebocontrolled trials clin infect dis doi pmid
external links
viropharmacom
